Allogene Therapeutics, Inc.
ALLO Healthcare Biotechnology
Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023. In the quarter to June 2026, revenue grew 20,990.9%, EPS grew 43.5% and free cash flow grew 17.7%, each against the same quarter a year earlier.
Follow ALLO
Allogene Therapeutics, Inc. (ALLO) EV/Sales
As of 16 October 2026, Allogene Therapeutics, Inc. (ALLO) trades at a EV/Sales of 20.9×. Over the past ten years it has ranged from −2,449× (November 2023) to 6,278× (July 2023); the current reading is higher than 59% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 1,408× | 12.01% |
| FY2023 | 1,257× | (36.18%) |
| FY2022 | 1,969× | 14,218.30% |
| FY2021 | 13.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 74.7× | (98.17%) |
| Mar 2024 | 4,091× | 225.51% |
| Dec 2023 | 1,257× | (21.17%) |
| Sep 2023 | 1,594× | (59.07%) |
| 10 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ARVN Arvinas, Inc. compare | −0.4× |
| NGNE Neurogene Inc. compare | n/m |
| RGNX REGENXBIO Inc. compare | 1.5× |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | 2.6× |
| ALLO Allogene Therapeutics, Inc. | 20.9× |
| OCS Oculis Holding AG compare | 109× |
| CBIO Crescent Biopharma, Inc. compare | 187× |
| ALT Altimmune, Inc. compare | 2,534× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)